This paper is in the following e-collection/theme issue:

Cardiology (161) Health Services Research (487)

Published on in Vol 11, No 2 (2022): Jul-Dec

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/39778, first published .
Ranolazine Versus Allopurinol for Eligible Symptomatic Patients With a History of Angioplasty: Comparative Efficacy Study

Ranolazine Versus Allopurinol for Eligible Symptomatic Patients With a History of Angioplasty: Comparative Efficacy Study

Ranolazine Versus Allopurinol for Eligible Symptomatic Patients With a History of Angioplasty: Comparative Efficacy Study

Authors of this article:

Reza Rahmani1 Author Orcid Image ;   Ehsan Moradi Farsani1 Author Orcid Image ;   Sima Bahrami1 Author Orcid Image
Article Authors Cited by (2) Tweetations (2) Metrics

Journals

  1. Cesar L, Mioto B. Allopurinol versus Trimetazidine as Antianginal: A Randomized Clinical Trial. Arquivos Brasileiros de Cardiologia 2024;121(8) View
  2. Cesar L, Mioto B. Alopurinol versus Trimetazidina como Antianginal: Um Ensaio Clínico Randomizado. Arquivos Brasileiros de Cardiologia 2024;121(8) View